Exciting biotech company is analyzed by StockCharts365.com
In this week’s Analysis (week 42), StockCharts365.com takes a closer look at an exciting biotech company on the Stockholm Stock Exchange
Isofol Medical AB
(Ticker on Nasdaq Stockholm: ISOFOL)
Isofol Medical AB (publ) wants to improve the quality of life and increase survival rates for patients with serious forms of cancer. The company’s drug candidate arfolitixorin aims to increase the efficacy of the first-line standard of care for several forms of solid tumors, including colon cancer. The next step in the clinical development program is now being prepared based on a new dosing regimen that is expected to optimize the efficacy of the drug candidate. Colorectal cancer (CRC) is the third most common cancer in the world and there is a large need for effective drugs to treat this disease.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
More information and technical analysis for Isofol below.
First Vikingen Investment School
Here you find our comments for week 42:
MPC Container Ships we choose to keep. Good share in the slightly longer term.
NVIDIA stock is starting to move upwards, and last week last week we saw a symmetrical triangle formation (i.e. falling tops and rising bottoms) indicating buy/hold..
We choose to keep Neobo Fastigheter AB , the share continues to show an upward trend and the target price has been increased.
Questerre Energy Corp (QEC) We keep this share, but we are monitoring it.
Ambea AB a Swedish healthcare company, we purchase this share with the money we received from previous sales.
That was this week’s investment school. Feel free to give us feedback and follow us on FB and/or Linkedin.
Biotechnology = high risk
Let it be said, that investing in biotechnology companies clearly involves a VERY HIGH RISK, but then there was this thing about ‘Nothing ventured, nothing gained…’ StockCharts365.com finds Isofol Medical AB (ISOFOL) an exciting and interesting stock, both technically and fundamentally, but emphasizes that investing in biotechnology companies undoubtedly involves a high risk.
That said, there is also enormous potential if biotech companies succeed. As the charts below show, the Isofol share price has fluctuated widely, both up and down, in recent years. Below are two stock exchange announcements and news stories that can explain some of these major fluctuations, down and up.
Price development for the Isofol share
As we can see from the charts of the price development of the Isofol share, it fell sharply in August 2022, and here is a link to the news and stock exchange announcement at the time, which says a little about the background for the sharp price drop for the Isofol share in August 2022, 03.
August 2022 – Isofol Announces Topline Results of Phase III AGENT Study – did Not Meet Primary or Key Secondary Endpoints. Read the full story and the stock exchange announcement here
Significant increase in Isofol share volume since July 2024
Then we see from the charts above that the Isofol share has risen sharply under a significant increase in volume since July 05, 2024, and a news and stock exchange announcement from July 05, 2024 explains some of the background to the start of this sharp rise for the share.
Isofol announces that a per-protocol post hoc analysis of the AGENT study provides further support for arfolitixorin’s continued clinical development. Read the story and stock exchange announcement here
Technical Analysis of Isofol Medical AB
(Ticker on Nasdaq Stockholm: ISOFOL)
The Isofol share has shown a strong development since the beginning of July 2024, where the share multiplied in a short period of time. The share has recently consolidated, but is now showing signs of breaking out of this consolidation formation. There was a sharp increase in volume for the share during the upturn in July/August, and then the volume fell back during the latest consolidation. This indicates a positive volume balance for the share and supports the positive technical picture for the share. After breaking out of such consolidation formations as we are now seeing for the ISOFOL share, we can expect a similarly strong rise as the rise before the consolidation.
This indicates that the ISOFOL share has the potential to rise to around SEK 10.00 – 20.00 in as short a time as the next 3-6 months (the upturn after breaking out of such consolidation formations often takes place over the same length of time as the previous upturn, in this case within a few months). Momentum indicators such as RSI and MACD signal a further rise for the share in the short term.
The BEST model in Vikingen also shows a buy signal for Isofol
The BEST model in Vikingen also indicates a buy signal for Isofol. This popular and effective technical analysis model was developed by Peter Östevik. He finalized the BEST model around 2019, after 30 years of experience with technical analysis and Vikingen Financial Software.
Isofol is a very exciting buy candidate, but…
StockCharts365.com finds the ISOFOL share a very exciting buy candidate, but emphasizes that investing in biotechnology stocks involves a high risk, but the potential can also be large.
Stock chat with Aktieutbildning.nu & Vikingen Financial Software
Every Wednesday 7-8 CET, join online here
Mikael Hellberg at Aktieutbildning.nu is a highly experienced stock and fund manager whose extensive knowledge you can benefit from. Read more about how below and participate in the Stock chat!
Earn more – find out how…
How do we build a large capital?
How do we get a higher pension?
How do we find the winners in the stock market?
What is Vikingen Investment School?
Vikingen Investment School (the content of which we talk about in this blog) started on May 13, 2024. We have chosen to invest 10,000 SEK and hope that you will join us to learn how to get rich(er) on the stock market. If you have more than 10 000 SEK to invest, it’s of course even more interesting, but the principles are the same. Through Vikingen Financial Software and our mentor Peter Östevik, we at Vikingen Investment School select the investments that are most worth buying right now. Since 10/6, we’re adding even more value to the blog by adding “Analysis of the week” from StockCharts365. com. And since week 41, there is a link to Stock chat in this blog.
Vikingen has a great offer!
Right now you receive 25% discount on Viking Exchange!
Our best-selling subscription.
Welcome to sign up! Use the code VIKNU2024
The discount is valid until 31/10 2024, on annual subscriptions, and cannot be combined with other offers. Vikingen Financial Software reminds you that past performance does not always indicate future profits and that all trading is at your own risk.
Sincerely, Catrin Abrahamsson-Beynon
